

Table 1: Top Drug Claims Data Reviewed by the DUR Board

NOTE: if an entry is not included in the drop-down box list, please select ‘other’ at end of the list and enter a free form response in the box below.

Column 1 Top 10 PA Requests by Drug Name, report at generic ingredient level	Column 2 Top 10 PA Requests by Drug Class	Column 3 Top 5 Claim Denial Reasons (i.e. Quantity Limits (QL), Early Refill (ER), PA, Therapeutic Duplications (TD), and Age Edits (AE))	Column 4 Top 10 Drug Names by Amount Paid, report at generic ingredient level	Column 5 % of Total Spent for Drugs by Amount Paid (From data in Column 4, determine the % of total drug spend)	Column 6 Top 10 Drug Names by Claim Count, report at generic ingredient level	Column 7 Drugs by Claim Count % of Total Claims (From data in Column 6, determine the % of total claims)
				%		%
				%		%
				%		%
				%		%
				%		%
				%		%
				%		%
				%		%
				%		%
				%		%
				%		%

Table 3: Top Opioid Controlled Substances by Population

Population	Column 1 Number of Beneficiaries Within Each Age Group	Column 2 Number of Unique Beneficiaries Within Each Age Group Receiving an Opioid Controlled Substance in the 12 Month Reporting Period	Column 3 Percentage of Unique Beneficiaries Within Each Age Group Receiving an Opioid Controlled Substances in the 12 Month Reporting Period	Column 4 Top 3 Opioid Controlled Substances Received Within Each Age Group (<i>Generic Ingredient</i>) in the 12 Month Reporting Period	Column 5 Number of Unique Beneficiaries Within Each Age Group Receiving the Opioid Controlled Substance (Specified in Column 4) in the 12 Month Reporting Period	Column 6 Percentage of Unique Beneficiaries Within Each Age Group Receiving the Top 3 Opioid Controlled Substance (Specified in Column 4) in the 12 Month Reporting Period
0-18 yrs.			%			%
						%
						%
19-29 yrs.			%			%
						%
						%
30-39 yrs.			%			%
						%
						%
40-49 yrs.			%			%
						%
						%
50-59 yrs.			%			%
						%
						%
60-69 yrs.			%			%
						%
						%
70-79 yrs.			%			%
						%
						%
80+ yrs.			%			%
						%
						%
Individuals with Disabilities Utilizing State Eligibility Categories			%			%
						%
						%

Table 4: Top Sedative/Benzodiazepine Controlled Substances by Population - When listing the controlled substances in different drug categories, for the purpose of Table 4 below, please consider long and short acting benzodiazepines to be in the same category.

Population	Column 1 Number of Beneficiaries Within Each Age Group	Column 2 Number of Unique Beneficiaries Within Each Age Group Receiving a Sedative/Benzodiazepine in the 12 Month Reporting Period	Column 3 Percentage of Unique Beneficiaries Within Each Age Group Receiving a Sedative/Benzodiazepine in the 12 Month Reporting Period	Column 4 Top 3 Sedative/Benzodiazepine Received Within Each Age Group (Generic Ingredient) in the 12 Month Reporting Period	Column 5 Number of Unique Beneficiaries Within Each Age Group Receiving the Sedative/Benzodiazepine (Specified in Column 4) in the 12 Month Reporting Period	Column 6 Percentage of Unique Beneficiaries Within Each Age Group Receiving the Top 3 Sedative/Benzodiazepine (Specified in Column 4) in the 12 Month Reporting Period
0-18 yrs.			%			%
						%
						%
19-29 yrs.			%			%
						%
						%
30-39 yrs.			%			%
						%
						%
40-49 yrs.			%			%
						%
						%
50-59 yrs.			%			%
						%
						%
60-69 yrs.			%			%
						%
						%
70-79 yrs.			%			%
						%
						%
80+ yrs.			%			%
						%
						%
Individuals with Disabilities Utilizing State Eligibility Categories			%			%
						%
						%

Table 5: Top Stimulant/ADHD Controlled Substances by Population -When listing the controlled substances in different drug categories, for the purpose of Table 5 below, please consider long and short acting ADHD medications to be in the same category.

Population	Column 1 Number of Beneficiaries Within Each Age Group	Column 2 Number of Unique Beneficiaries Within Each Age Receiving a Stimulant/ADHD Medication in the 12 Month Reporting Period	Column 3 Percentage of Unique Beneficiaries Within Each Age Group Receiving a Stimulant/ADHD Medication in the 12 Month Reporting Period	Column 4 Top 3 Stimulant/ADHD Medication Within Each Age Group (Generic Ingredient) in the 12 Month Reporting Period	Column 5 Number of Unique Beneficiaries Within Each Age Group Receiving a Stimulant/ADHD Medication (Specified in Column 4) in the 12 Month Reporting Period	Column 6 Percentage of Unique Beneficiaries Within Each Age Group Receiving the Top 3 Stimulant/ADHD Medication (Specified in Column 4) in the 12 Month Reporting Period
0-18 yrs.			%			%
						%
						%
19-29 yrs.			%			%
						%
						%
30-39 yrs.			%			%
						%
						%
40-49 yrs.			%			%
						%
						%
50-59 yrs.			%			%
						%
						%
60-69 yrs.			%			%
						%
						%
70-79 yrs.			%			%
						%
						%
80+ yrs.			%			%
						%
						%
Individuals with Disabilities Utilizing State Eligibility Categories			%			%
						%
						%